GobyMeds

About GobyMeds

GoByMeds is one of the newest providers in our coverage, founded in 2023. Despite its youth, the platform has carved out a distinct niche by offering both compounded and brand-name GLP-1 medications, including Zepbound and Wegovy, at monthly costs between $99 and $133. This pricing structure is notably competitive for a provider that includes brand-name options — most competitors offering FDA-approved GLP-1s charge substantially more, making GoByMeds an outlier worth examining closely.

Early trust signals are positive. On Trustpilot, GoByMeds holds a 4.5 rating across 220+ reviews, a strong score for a company less than two years old. The B+ BBB rating further supports the impression of a well-run operation. While the review volume is still modest compared to established players, the quality of early sentiment is encouraging and suggests GoByMeds is building a solid reputation from the ground up.

GoByMeds differentiates itself with starter bundles designed to reduce the friction of beginning GLP-1 therapy. These bundles typically include the initial consultation, first month of medication, and basic supplies at a single transparent price. For patients overwhelmed by the fragmented pricing models of many telehealth providers — where consultation fees, medication costs, shipping, and supplies are all itemized separately — the bundle approach simplifies the decision. The clinical support model is medium-tier, with standard provider check-ins and prescription management.

A standout feature is GoByMeds’ explicit PCOS support. Polycystic ovary syndrome affects an estimated 6-12% of women of reproductive age and is strongly associated with insulin resistance and weight gain. GLP-1 medications have shown particular promise for women with PCOS, and GoByMeds’ willingness to specifically market to and support this population indicates clinical awareness that goes beyond generic weight loss prescribing. For women with PCOS who have struggled to find providers who understand the hormonal complexity of their weight management challenges, this is a meaningful differentiator.

The primary concern with GoByMeds is its limited track record. A 2023 founding date means the company has less than two years of operational history, and the relatively small Trustpilot volume — while positive — does not yet provide the statistical confidence of a 5,000+ review dataset. The medium-support model also means patients needing intensive clinical oversight or nutrition coaching will need to supplement GoByMeds’ services independently. Still, the combination of accessible pricing, brand-name availability, and PCOS awareness makes GoByMeds a provider to watch as it matures.

At a Glance